A Novel Cancer Vaccine Meets Canine Trial Endpoints
Michael Lawman, Curtis Kane, Shabnam Eidizadeh, Neil Shaw, Laura Xijaco & Pat Lawman
St. Joseph’s Children’s Hospital of Tampa, Tampa, FL • Florida Veterinary Specialists, Tampa, FL • Morphogenesis, Inc., Oldsmar, FL

SUMMARY
• All dogs enrolled in the study produced a strong humoral response to the vaccine in the absence of severe systemic reactions, including severe immunological or anaphylactic reactions. In fact, the sera of dogs treated with the vaccine showed strong reactivity to autologous tumor cells. This indicates that cancer vaccines can be effective and safe for dogs.

INTRODUCTION
• Canine lymphosarcoma is one of the most common types of cancer in dogs and has a high mortality rate. The development of a successful cancer vaccine for this disease is crucial for improving the quality of life for canine cancer patients.

MATERIALS AND METHODS
Clinical Assessment
• Clinical endpoints were evaluated using a scoring system to assess the clinical status of the dogs.

Cross-Reactivity of Canine Immune Serum

In Vitro Assessment
• Lysates of tumor cells treated with mitomycin C were analyzed using immunoblotting techniques to assess the immune response of the dogs to the vaccine.

Cell-mediated Response to ImmuneFx

ACKNOWLEDGEMENTS
The authors would like to acknowledge the continued financial support of The Pediatric Cancer Foundation, Inc. USA and ImmuneFx, Inc. USA.

DISCUSSION
• The clinical and in vitro results indicate that the cancer vaccine is effective and safe for dogs. This vaccine has the potential to be used as a treatment option for canine lymphosarcoma.

SPECIFIC END POINTS
- Patient Recruitment for the canine lymphosarcoma study began...
- The trial was designed to evaluate the efficacy and safety of the vaccine...
- The authors are grateful for the support of the University of Miami...

FINANCIAL SUPPORT
The authors declare no financial support from any other source...

IMMUNE RESPONSES
- Humoral responses in ImmuneFx vaccine-treated dogs...
- Cell-mediated responses in ImmuneFx vaccine-treated dogs...

SUMMARY OF CLINICAL RESPONSES
- Clinical responses in ImmuneFx vaccine-treated dogs...
- Summary of clinical responses in ImmuneFx vaccine-treated dogs...

AUTHOR CONTRIBUTIONS
- Michael Lawman, Curtis Kane, Shabnam Eidizadeh, Neil Shaw, Laura Xijaco, Pat Lawman, and Morphogenesis, Inc.,...